JPH0723309B2 - 癌治療薬剤 - Google Patents

癌治療薬剤

Info

Publication number
JPH0723309B2
JPH0723309B2 JP24642585A JP24642585A JPH0723309B2 JP H0723309 B2 JPH0723309 B2 JP H0723309B2 JP 24642585 A JP24642585 A JP 24642585A JP 24642585 A JP24642585 A JP 24642585A JP H0723309 B2 JPH0723309 B2 JP H0723309B2
Authority
JP
Japan
Prior art keywords
proline
hydroxy
cis
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP24642585A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61155324A (ja
Inventor
ヘルマン ヴイルヘルム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS61155324A publication Critical patent/JPS61155324A/ja
Publication of JPH0723309B2 publication Critical patent/JPH0723309B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
JP24642585A 1984-11-05 1985-11-05 癌治療薬剤 Expired - Fee Related JPH0723309B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66820084A 1984-11-05 1984-11-05
US72356585A 1985-04-15 1985-04-15
US668200 1985-04-15
US723565 2003-11-25

Publications (2)

Publication Number Publication Date
JPS61155324A JPS61155324A (ja) 1986-07-15
JPH0723309B2 true JPH0723309B2 (ja) 1995-03-15

Family

ID=27099851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24642585A Expired - Fee Related JPH0723309B2 (ja) 1984-11-05 1985-11-05 癌治療薬剤

Country Status (5)

Country Link
JP (1) JPH0723309B2 (de)
CA (1) CA1281288C (de)
CH (1) CH667591A5 (de)
DE (1) DE3538619C2 (de)
GB (1) GB2171302B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294380A4 (de) * 1986-02-18 1990-02-20 Biota Scient Management Stimulierung von angiogenese.
DE3728852C2 (de) * 1987-08-28 2003-06-18 Wilhelm Hoerrmann Arzneimittel zur Tumortherapie
EP0307390A3 (de) * 1987-09-04 1991-04-10 Merckle Gmbh Chemische Verbindung bestehend aus cis-3-hydroxyprolin zur therapeutischen Behandlung und Verfahren zu deren Herstellung
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
ES2152664T3 (es) * 1996-03-11 2001-02-01 Hoerrmann Wilhelm Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer.
AU2698997A (en) * 1996-04-16 1997-11-07 Chephasaar Chem.-Pharm. Fabrik Gmbh Agent for inhibiting leukocyte invasion of tissues
DE10359829A1 (de) * 2003-12-12 2005-07-21 Salama, Zoser B., Dr.Rer.Nat. Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
US20080176923A1 (en) * 2003-12-18 2008-07-24 Salama Zoser B Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors
WO2005120495A1 (en) * 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
EP1957066A4 (de) 2005-11-11 2013-08-28 V Ravi Chandran Acetylierte aminosäuren als thrombozytenaggregationshemmer, nahrungs- und vitamin-ergänzungsmittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7639M (de) * 1967-09-14 1970-02-02
US3932638A (en) * 1967-09-14 1976-01-13 Franco-Chimie S.A.R.L. Compositions and methods for wound healing
GB1399887A (en) * 1971-06-10 1975-07-02 Prockop D J Composition and methods for controlling collagen synthesis
FR2207702B1 (de) * 1972-11-23 1975-11-28 Rhone Poulenc Ind
JPS59164718A (ja) * 1983-03-10 1984-09-17 Advance Res & Dev Co Ltd 発癌予防剤

Also Published As

Publication number Publication date
DE3538619C2 (de) 1995-11-09
JPS61155324A (ja) 1986-07-15
CH667591A5 (de) 1988-10-31
GB2171302A (en) 1986-08-28
DE3538619A1 (de) 1986-05-07
CA1281288C (en) 1991-03-12
GB8527159D0 (en) 1985-12-11
GB2171302B (en) 1989-08-23

Similar Documents

Publication Publication Date Title
JP2806634B2 (ja) 前立腺癌，胃癌および乳癌に関連する腫瘍を抑制するための医薬製剤
US5200395A (en) Pharmaceutical composition of BUF-5 for treating anemia
JPH0723309B2 (ja) 癌治療薬剤
KR100595364B1 (ko) Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
KR20050040907A (ko) 항종양 활성 증강용 화학요법제의 조합
CN110064045B (zh) 微肽cip2a-bp在治疗癌症中的应用
CN116726021B (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
US11939399B2 (en) Synthetic peptide sp4 and use thereof
TWI606835B (zh) 基於靈芝多醣之組合物及治療癌症之方法
CN115463127A (zh) 鸦胆子苦醇联合17-aag作为pd-l1抑制剂的应用
CN114522158A (zh) 用于制备治疗肝癌药物的代谢物及其应用
CN117942345A (zh) 一种arv-825分子配体治疗nut癌方法
CN113456643B (zh) 一种含普那布林的药物组合及其应用
CN117338786A (zh) 一种治疗急性t淋巴细胞白血病及合并中枢神经系统白血病的联合用药物及其应用
CN115350176A (zh) 一种胃癌肿瘤细胞和胃癌肿瘤干细胞治疗药物及其应用
Shao et al. Influence of angiostatin and thalidomide on lymphangiogenesis
CN107349426A (zh) 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用
CN116077643A (zh) 治疗和/或预防肺癌的联合用药物及应用
CN113956344A (zh) 一种新型治疗肝癌的fgf类似物及其应用
Barut et al. Isolation and characterization of metastatic sublines from a murine transitional cell bladder carcinoma
CN119679939B (zh) 乳酰转移酶抑制剂在胰腺癌及其免疫治疗中的应用
CN112076216A (zh) 三氧化二砷在治疗胃肠道间质瘤中的应用
TWI607751B (zh) Statin compounds for the treatment of gastric cancer
CN115227690B (zh) 土木香内酯在双表达型b细胞淋巴瘤中的应用
Kitagawa et al. In vivo antimelanoma effects of 4-S-cysteaminylphenol, a newly synthesized therapeutic agent specific to melanoma

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees